Vital Therapies Announces Second Quarter 2018 Financial Results
07 août 2018 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast
31 juil. 2018 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Joins the Russell 3000 Index®
25 juin 2018 08h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, June 25, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
12 juin 2018 16h30 HE
|
Vital Therapies, Inc.
SAN DIEGO, June 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies to Present at the Jefferies 2018 Global Healthcare Conference
07 juin 2018 08h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, June 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Hosting Analyst R&D Day Today
24 mai 2018 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, May 24, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies to Host Analyst R&D Day on May 24, 2018
11 mai 2018 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces First Quarter 2018 Financial Results
08 mai 2018 16h01 HE
|
Vital Therapies, Inc.
- VTL-308 Enrollment Completed with 151 Subjects- On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc....
Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call with Webcast
26 avr. 2018 16h05 HE
|
Vital Therapies, Inc.
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 avr. 2018 16h30 HE
|
Vital Therapies, Inc.
SAN DIEGO, April 25, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...